Table 2 Meta-analysis of the association of the response to chemotherapy for OS patients and the rs11615, rs1799793, and rs13181 polymorphisms
SNP | Total patients (n) | Model | OR | Lower limit | Upper limit | P (OR) | I 2 (%) | P (Heterogeneity) | P (Begg’s test) | P (Egger’s test) | FSN |
|---|---|---|---|---|---|---|---|---|---|---|---|
rs11615 | 1019 | Dominant model (TT + TC/CC) | 2.015 | 1.242 | 3.271 | 0.005 | 53.30 | 0.073 | 0.462 | 0.168 | 25.000 |
Recessive model(TT/TC + CC) | 1.791 | 1.353 | 2.372 | 0.003 | 36.60 | 0.177 | 0.462 | 0.508 | 22.393 | ||
Allelic model(T/C) | 1.677 | 1.194 | 2.356 | 0.003 | 67.30 | 0.016 | 0.806 | 0.927 | 105.107 | ||
rs13181 | 1133 | Dominant model (AA + AC/CC) | 1.058 | 0.739 | 1.516 | 0.757 | <0.01 | 0.572 | 0.707 | 0.511 | 3.434 |
Recessive model(AA/AC + CC) | 1.135 | 0.868 | 1.484 | 0.355 | 16.10 | 0.31 | 0.26 | 0.079 | 3.160 | ||
Allelic model(A/C) | 1.091 | 0.894 | 1.331 | 0.392 | 37.40 | 0.157 | 0.452 | 0.271 | 14.151 | ||
rs1799793 | 949 | Dominant model (GG + GA/AA) | 1.54 | 0.982 | 2.413 | 0.06 | 22.30 | 0.272 | 0.221 | 0.317 | 44.628 |
Recessive model(GG/AG + AA) | 1.337 | 1.019 | 1.754 | 0.036 | 36.70 | 0.177 | 1.000 | 0.98 | 56.223 | ||
Allelic model(G/A) | 1.328 | 0.943 | 1.87 | 0.105 | 57.60 | 0.051 | 1.000 | 0.973 | 92.857 |